The proxy fight outcome is binary: management slate victory maintains current strategy and IP narrative; DOMA board seats could shift capital allocation and IP litigation approach. Vote outcome likely within weeks. Monitor for institutional proxy advisor recommendations (ISS/Glass Lewis) which will be decisive given activist holds <10% likely.
PCRX drugs
PCRX drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · May 27 $24.04entry
- T+1 · 6mo ago −1.50%α −2.05% · $23.68
- T+5 · 6mo ago −7.15%α −7.62% · $22.32
- T+20 · 5mo ago +1.37%α +3.27% · $24.37
- T+60 · 3mo ago −0.87%α −2.75% · $23.83
Price Chart
How similar events traded
Executive Summary
Pacira BioSciences issued a press release defending its intellectual property strategy against activist investor DOMA Perpetual Capital Management ahead of the 2026 annual meeting. The filing rebuts DOMA's claims about patent weakness, highlights the Fresenius Kabi settlement providing EXPAREL exclusivity through early 2030, and urges stockholders to vote for management's three board nominees on the BLUE proxy card.
Key Financial Metrics
Key Facts
- Activist DOMA Perpetual Capital Management has nominated three director candidates for Pacira's 2026 annual meeting
- Pacira's Fresenius Kabi settlement provides full EXPAREL exclusivity through early 2030 with gradual capped market entry until 2039
- Pacira has 21 Orange Book-listed patents across two families, with the newer IVRA family (940 patent) providing protection into July 2044
- Two recent Paragraph IV generic challenges have been filed, but Pacira notes these are early-stage ANDA filings without proven bioequivalence
- Goldman Sachs is acting as financial advisor and Perkins Coie as legal counsel to Pacira
Financial Impact
No specific financial figures provided; EXPAREL exclusivity runway through 2030 is the key commercial value driver
Risk Factors
- Activist wins board seats, potentially altering IP litigation strategy or pushing for sale
- Generic challenges to EXPAREL succeed despite Pacira's patent defense, eroding revenue base
- Patent litigation outcomes remain uncertain; IVRA family patents untested in court
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEFA14A Filing (Primary) | 0001628280-26-038111 |
| Document: 0001628280-26-038111-index-headers.html | 0001628280-26-038111 |
| Document: 0001628280-26-038111-index.html | 0001628280-26-038111 |
| Document: 0001628280-26-038111.txt | 0001628280-26-038111 |
Track record
29 reports on PCRX
5 of 7 bullish or bearish reports moved the stock their way by T+20. Best: +42.26% at T+60 after the Aug 6, 2026 report. 8 of 9 went positive at some point.
Filters
- Nov 12, 20264d ago 8-K Bearish 6/10 Entry $36.46 Now $36.48 −0.05% settles Dec 14
- Nov 12, 20264d ago SC TO-T/A Mixed 7/10 Entry $36.46 Now $36.48 +0.05% settles Dec 14
- Nov 12, 20264d ago SC 14D-9/A Neutral 3/10 Entry $36.46 Now $36.48 +0.05% settles Dec 14
- Nov 5, 202611d ago 8-K Neutral 5/10 Entry $36.43 Now $36.48 +0.14% settles Dec 7
- Nov 3, 202613d ago SC 14D-9/A Neutral 3/10 Entry $36.40 Now $36.48 +0.22% settles Dec 3
- Oct 30, 202617d ago SC 13G/A Neutral 2/10 Entry $36.39 Now $36.48 +0.25% settles Nov 30
- Oct 30, 202617d ago SC 14D-9 Bullish 7/10 Entry $36.39 Now $36.48 +0.25% settles Nov 30
- Oct 30, 202617d ago SC TO-T Mixed 7/10 Entry $36.39 Now $36.48 +0.25% settles Nov 30
- Oct 13, 20264w ago SC 13D/A Bearish 7/10 Entry $36.40 to $36.46 Now $36.48 −0.22% ▼ −0.16% −1.44% vs SPY
- Oct 8, 20265w ago SC TO-C Bullish 7/10 Entry $36.31 to $36.43 Now $36.48 +0.47% ▲ +0.33% +5.89% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers